16,620 Shares in Danaher Co. (NYSE:DHR) Bought by Norden Group LLC

Norden Group LLC purchased a new stake in Danaher Co. (NYSE:DHR) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 16,620 shares of the conglomerate’s stock, valued at approximately $4,151,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Cary Street Partners Investment Advisory LLC increased its position in Danaher by 20.2% during the 4th quarter. Cary Street Partners Investment Advisory LLC now owns 9,128 shares of the conglomerate’s stock valued at $2,112,000 after purchasing an additional 1,533 shares during the period. First Citizens Bank & Trust Co. increased its position in shares of Danaher by 0.6% during the fourth quarter. First Citizens Bank & Trust Co. now owns 26,611 shares of the conglomerate’s stock worth $6,156,000 after buying an additional 149 shares during the period. Cercano Management LLC raised its stake in Danaher by 11.4% during the fourth quarter. Cercano Management LLC now owns 202,569 shares of the conglomerate’s stock worth $46,862,000 after buying an additional 20,715 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in Danaher by 48.1% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate’s stock valued at $68,707,000 after buying an additional 96,395 shares during the period. Finally, Caden Capital Partners LP boosted its position in Danaher by 12.4% during the fourth quarter. Caden Capital Partners LP now owns 139,068 shares of the conglomerate’s stock valued at $32,172,000 after acquiring an additional 15,313 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of DHR opened at $240.21 on Thursday. The firm has a market capitalization of $177.92 billion, a P/E ratio of 40.71, a P/E/G ratio of 3.68 and a beta of 0.83. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $269.11. The stock has a 50 day moving average price of $255.88 and a two-hundred day moving average price of $246.95. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.51 and a current ratio of 1.85.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. During the same quarter in the prior year, the company posted $2.36 earnings per share. Danaher’s revenue was down 2.6% compared to the same quarter last year. Equities analysts forecast that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. The ex-dividend date of this dividend is Friday, June 28th. Danaher’s payout ratio is currently 18.31%.

Insider Buying and Selling

In other Danaher news, CEO Rainer Blair sold 9,005 shares of the stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $265.00, for a total value of $2,386,325.00. Following the completion of the sale, the chief executive officer now owns 106,990 shares in the company, valued at approximately $28,352,350. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other Danaher news, CEO Rainer Blair sold 9,005 shares of the business’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $265.00, for a total value of $2,386,325.00. Following the transaction, the chief executive officer now owns 106,990 shares of the company’s stock, valued at $28,352,350. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Matthew Mcgrew sold 46,377 shares of the firm’s stock in a transaction on Friday, May 10th. The shares were sold at an average price of $253.05, for a total value of $11,735,699.85. Following the sale, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at $7,441,441.35. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 148,783 shares of company stock worth $37,536,717. 10.90% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research analysts have recently weighed in on DHR shares. Jefferies Financial Group began coverage on Danaher in a research report on Monday, June 3rd. They issued a “buy” rating and a $295.00 price objective for the company. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. HSBC upgraded Danaher from a “hold” rating to a “buy” rating and increased their price target for the stock from $250.00 to $280.00 in a report on Wednesday, April 17th. Evercore ISI lowered their price objective on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a research note on Tuesday. Finally, Citigroup increased their target price on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Six research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and a consensus target price of $268.67.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.